MX2012015305A - Compuestos heterociclicos, su preparacion y su aplicacion terapeutica. - Google Patents

Compuestos heterociclicos, su preparacion y su aplicacion terapeutica.

Info

Publication number
MX2012015305A
MX2012015305A MX2012015305A MX2012015305A MX2012015305A MX 2012015305 A MX2012015305 A MX 2012015305A MX 2012015305 A MX2012015305 A MX 2012015305A MX 2012015305 A MX2012015305 A MX 2012015305A MX 2012015305 A MX2012015305 A MX 2012015305A
Authority
MX
Mexico
Prior art keywords
preparation
heterocyclic compounds
therapeutic application
methods
ameliorating
Prior art date
Application number
MX2012015305A
Other languages
English (en)
Inventor
Caroline Leriche
David Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of MX2012015305A publication Critical patent/MX2012015305A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención está dirigida a determinados compuestos nuevos, a los métodos para producirlos y a los métodos para tratar o mejorar un trastorno mediado por quinasa.
MX2012015305A 2010-06-22 2011-06-22 Compuestos heterociclicos, su preparacion y su aplicacion terapeutica. MX2012015305A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305665 2010-06-22
PCT/EP2011/060445 WO2011161159A1 (en) 2010-06-22 2011-06-22 Heterocyclic compounds, their preparation and their therapeutic application

Publications (1)

Publication Number Publication Date
MX2012015305A true MX2012015305A (es) 2013-05-30

Family

ID=43033247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012015305A MX2012015305A (es) 2010-06-22 2011-06-22 Compuestos heterociclicos, su preparacion y su aplicacion terapeutica.

Country Status (27)

Country Link
US (1) US20130123271A1 (es)
EP (1) EP2585439A1 (es)
JP (1) JP2013533237A (es)
KR (1) KR20130116070A (es)
CN (1) CN103140480A (es)
AR (1) AR081960A1 (es)
AU (1) AU2011268938A1 (es)
BR (1) BR112012032721A2 (es)
CA (1) CA2803496A1 (es)
CL (1) CL2012003637A1 (es)
CO (1) CO6660505A2 (es)
CR (1) CR20120653A (es)
DO (1) DOP2012000317A (es)
EA (1) EA201291329A1 (es)
EC (1) ECSP12012354A (es)
GT (1) GT201200345A (es)
IL (1) IL223721A0 (es)
MA (1) MA34384B1 (es)
MX (1) MX2012015305A (es)
NI (1) NI201200193A (es)
NZ (1) NZ605022A (es)
PE (1) PE20130640A1 (es)
SG (1) SG186424A1 (es)
TN (1) TN2012000610A1 (es)
TW (1) TW201204723A (es)
UY (1) UY33461A (es)
WO (1) WO2011161159A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
JP2016527193A (ja) * 2013-06-07 2016-09-08 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジン
BR112015030774A2 (pt) * 2013-06-10 2017-07-25 Bayer Pharma AG novos compostos para o tratamento de câncer
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
EP3237414B1 (en) 2014-12-24 2019-05-08 Gilead Sciences, Inc. Fused pyrimidine compounds for the tratment of hiv
AU2015371257B2 (en) 2014-12-24 2018-09-06 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of HIV
EP3390387B1 (en) 2015-12-18 2021-11-17 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
KR102435905B1 (ko) * 2016-04-08 2022-08-26 베이롤 칼리지 오브 메드신 스테로이드 수용체 공활성제의 소분자 조절제 및 이의 사용 방법
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
CN115916759A (zh) * 2020-06-19 2023-04-04 南京红云生物科技有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
AU1462101A (en) 1999-11-22 2001-06-04 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
WO2004065378A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
AU2004281154A1 (en) 2003-10-16 2005-04-28 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
CA2578283A1 (en) 2004-08-25 2006-03-02 Targegen, Inc. Heterocyclic compounds and methods of use
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101155799A (zh) 2005-03-16 2008-04-02 塔格根公司 嘧啶化合物和使用方法
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
BRPI0606172A2 (pt) 2005-06-08 2009-06-02 Targegen Inc métodos e composições para o tratamento de distúrbios oculares
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
WO2008020203A1 (en) 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
WO2008079988A2 (en) 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2226315A4 (en) 2007-12-28 2012-01-25 Carna Biosciences Inc 2-AMINOQUINAZOLINE DERIVATIVE
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
MA32968B1 (fr) 2008-12-29 2012-01-02 Fovea Pharmaceuticals Composes quinazoline substitues
BRPI1008850A2 (pt) * 2009-02-13 2016-03-15 Fovea Pharmaceuticals [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase

Also Published As

Publication number Publication date
NI201200193A (es) 2013-05-13
MA34384B1 (fr) 2013-07-03
PE20130640A1 (es) 2013-03-30
EP2585439A1 (en) 2013-05-01
CR20120653A (es) 2013-04-03
CN103140480A (zh) 2013-06-05
NZ605022A (en) 2013-12-20
GT201200345A (es) 2014-01-24
AR081960A1 (es) 2012-10-31
AU2011268938A1 (en) 2013-01-24
CL2012003637A1 (es) 2013-07-05
SG186424A1 (en) 2013-01-30
JP2013533237A (ja) 2013-08-22
KR20130116070A (ko) 2013-10-22
UY33461A (es) 2012-01-31
CO6660505A2 (es) 2013-04-30
BR112012032721A2 (pt) 2016-11-29
TN2012000610A1 (en) 2014-04-01
EA201291329A1 (ru) 2013-05-30
TW201204723A (en) 2012-02-01
ECSP12012354A (es) 2013-01-31
US20130123271A1 (en) 2013-05-16
WO2011161159A1 (en) 2011-12-29
DOP2012000317A (es) 2013-04-15
CA2803496A1 (en) 2011-12-29
IL223721A0 (en) 2013-03-05

Similar Documents

Publication Publication Date Title
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
PH12017501139A1 (en) Novel modulators and methods of use
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
MX2011007930A (es) Conjugados de insulina cristalina.
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013003309A (es) Compuestos de benzamida sustituidos.
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
MY181828A (en) Bicyclically substituted uracils and the use therapy
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
PH12015501038A1 (en) Inhibitors of iap
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
PH12015500399A1 (en) Azaindolines
PH12017500270A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain
IN2014DN03010A (es)
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
TN2014000391A1 (en) Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
MX2013006526A (es) Dosis de los derivados de arilsulfonamida.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal